Citizens Financial Group Inc. RI Purchases New Shares in Immunome, Inc. $IMNM

Citizens Financial Group Inc. RI purchased a new position in Immunome, Inc. (NASDAQ:IMNM) during the second quarter, Holdings Channel.com reports. The firm purchased 20,000 shares of the company’s stock, valued at approximately $424,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. KBC Group NV purchased a new stake in Immunome during the first quarter valued at about $60,000. BNP Paribas Financial Markets boosted its holdings in shares of Immunome by 81.8% in the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after buying an additional 2,909 shares during the period. Strs Ohio purchased a new position in shares of Immunome in the fourth quarter worth approximately $64,000. Tower Research Capital LLC TRC increased its position in shares of Immunome by 121.2% in the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock worth $65,000 after acquiring an additional 3,802 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Immunome during the third quarter valued at approximately $76,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Stock Performance

IMNM stock opened at $28.08 on Friday. The firm has a 50 day simple moving average of $22.98 and a 200 day simple moving average of $22.30. Immunome, Inc. has a 52 week low of $8.66 and a 52 week high of $30.06. The stock has a market cap of $3.19 billion, a P/E ratio of -11.10 and a beta of 2.08.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.14). Sell-side analysts predict that Immunome, Inc. will post -2.38 EPS for the current year.

Insider Buying and Selling at Immunome

In other news, Director Isaac Barchas sold 11,048 shares of the company’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $27.25, for a total value of $301,058.00. Following the transaction, the director directly owned 92,211 shares of the company’s stock, valued at approximately $2,512,749.75. This represents a 10.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Robert Lechleider sold 55,000 shares of the stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $22.62, for a total value of $1,244,100.00. Following the sale, the insider owned 15,805 shares of the company’s stock, valued at approximately $357,509.10. This represents a 77.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 682,310 shares of company stock valued at $15,675,566 in the last quarter. Company insiders own 7.21% of the company’s stock.

Analysts Set New Price Targets

IMNM has been the subject of several research analyst reports. Barclays began coverage on shares of Immunome in a research report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price target for the company. Wedbush lifted their price objective on shares of Immunome from $31.00 to $35.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. HC Wainwright reissued a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Wall Street Zen lowered Immunome from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Finally, Leerink Partners decreased their target price on Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research report on Friday, May 15th. Twelve research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $34.64.

Immunome Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.